SCHEMBL7230674

SCHEMBL7230674

CCOC(=O)C(Cc1ccc(B2OC(C)(C)C(C)(C)O2)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.48
ITGB3 P05106 1/20 0.44
ITGA2B P08514 1/20 0.44
CTSS P25774 6/20 0.43
CTSK P43235 5/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
ACE P12821 1/20 0.41
F2 P00734 1/20 0.41
F11 P03951 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419294 1.00 AAK1 (0.48) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL17459578 0.92 AAK1 (0.51) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL21732913 0.92 AAK1 (0.51) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL17459580 0.92 AAK1 (0.51) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL539839 0.91 AAK1 (0.50) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL539840 0.91 AAK1 (0.50) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL30400176 0.91 AAK1 (0.50) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL16469777 0.88 AAK1 (0.50) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL15615749 0.88 CTSS (0.49) AAK1ITGB3ITGA2BCTSSCTSK
SCHEMBL16934587 0.88 CTSS (0.49) AAK1ITGB3ITGA2BCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026226-A1 POLYETHYLENE GLYCOL SMALL MOLECULE DRUG, PREPARATION METHOD THEREFOR AND USE THEREOF 重庆阿普格雷生物科技有限公司 2025-02-06 WO disclosed
US-6613782-B2 For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders NOVARTIS AG (CH) 2003-09-02 US disclosed
US-6423727-B1 Certain thiol inhibitors of endothelin-converting enzyme NOVARTIS AG (CH) 2002-07-23 US disclosed
US-20020082218-A1 Certain thiol inhibitors of endothelin-converting enzyme LOMBAERT STEPHANE DE (US) 2002-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082218-A1 Certain thiol inhibitors of endothelin-converting enzyme ECE1, ECE2, EDNRB AAK1 3844/4885ITGB3 2993/4885ITGA2B 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.